ABSTRACT
This chapter presents classification & mode of action, indications & dermatological uses, formulations/presentation, dosages & suggested regimens, baseline investigations, considerations & monitoring, contraindications, cautions, important drug interactions, and adverse effects & their management, of Propranolol. Propranolol was the first successful beta-adrenoceptor antagonist to be used medically following its discovery by James Black in 1962. Propranolol is licensed for use in cardiovascular disease, essential tremor and migraine prophylaxis. In 2014, The Food and Drug Administration and European medicines association granted marketing authorisation for a new oral solution of propranolol, Hemangiol® for proliferating infantile haemangiomas. Oral solutions of propranolol are available in several concentrations ranging from 1mg/ml-10mg/ml. Propranolol should be temporarily discontinued during episodes of viral induced wheeze or chest infection. Propranolol should be discontinued during inter current illness associated with restricted oral intake and if the infant is undergoing procedures requiring fasting, due to the increased risk of hypoglycaemia.
